Key Stats for Colgate-Palmolive Stock
- Past-Week Performance: -4.2%
- 52-Week Range: $74.6 to $99.3
- Current Price: $85.5
What Happened?
Colgate-Palmolive (CL) posted record operating cash flow of $4.2 billion in FY2025, even as a $919 million non-cash impairment on its skin health unit — primarily the Filorga premium skincare brand — dragged GAAP operating profit down 23% to $3.31 billion, leaving the stock trading at $85.68, well below its 52-week high of $99.33.
The February 23 annual filing confirmed non-GAAP diluted EPS of $3.69, up 3% despite the impairment, with Hill’s Pet Nutrition — the company’s premium veterinary and science-based pet food division — growing net sales 2.9% to $4.61 billion and delivering underlying volume growth of 2% once the company’s planned exit from lower-margin private label contracts is stripped out.
Organic sales growth of 1.4% for the full year masked a sharper exit-rate, with emerging markets posting approximately 4.5% organic growth in Q4 and Hill’s U.S. underlying revenue running at mid-single digits, outpacing a roughly flat domestic pet food category and widening its lead over mass-market pet nutrition rivals in the premium therapeutic segment.
CEO Noel Wallace stated on the Q4 2025 earnings call that “our ability to deliver dollar-based earnings per share growth in a year with that much volatility is a sign that the flexibility and resilience we have built into our operating model is working effectively to drive value for our shareholders,” tying directly to the Board’s authorization of a 63rd consecutive annual dividend increase.
Colgate’s newly launched 2030 strategy, underpinned by a Strategic Growth and Productivity Program carrying $200 to $300 million in cumulative pretax charges through 2028, targets 3% to 5% long-term organic sales growth by scaling AI-driven innovation tools, data clean rooms covering 70% of Hill’s U.S. media spend, and the Colgate brand’s position in roughly 60% of the world’s households.
Wall Street’s Take on CL Stock
Record operating cash flow of $4.2 billion in FY2025 validates the bull case: Colgate’s normalized earnings engine is intact even after the Filorga impairment, positioning the FY2026 EPS ramp toward $3.88 as credible rather than aspirational.
The TIKR estimates projects normalized EPS growing from $3.69 in FY2025 to $4.99 by FY2030, a trajectory grounded in SGPP-driven cost savings, Hill’s Pet Nutrition outgrowing a flat domestic category at mid-single digits, and gross margin holding above 60%.
Analysts covering CL are broadly constructive but measured: 6 buys, 6 outperforms, 7 holds, 1 underperform, and 1 sell across 19 estimates put the mean price target at $97.26, implying 13.8% upside from the current $85.49 as the Street awaits proof that North American category softness has bottomed.
The $88 low target reflects a scenario where U.S. category growth stays depressed and the 1% to 4% organic sales guidance range skews toward its floor; the $105 high assumes Hill’s private label drag clears after Q2 and SGPP savings accelerate.
What Does the Valuation Model Say?
The TIKR mid-case target of $125.99 implies a 47.4% total return over 4.8 years at an 8.5% IRR, anchored to a 3.5% revenue CAGR and net income margin expansion from 14.7% to 15.7%, a reasonable path given Colgate’s $200 to $300 million SGPP program and Hill’s scaling AI-driven omnichannel demand tools.
The market is discounting CL at a price implying the Filorga impairment defines the earnings story; normalized EPS of $3.69 in FY2025 says otherwise.
Hill’s mid-single-digit U.S. underlying growth and 70% of media spend running through data clean rooms that doubled conversion rates justify the TIKR model’s 3.5% revenue CAGR assumption and its $125.99 price target.
The Board’s 63rd consecutive dividend increase and record $4.2 billion operating cash flow signal management confidence in the normalized earnings trajectory, not distress.
A sustained deterioration in North American category volumes beyond current guidance would pressure the 1% to 4% organic sales range toward its floor and compress the EBITDA margin expansion path from 24.4% toward 25.5% by FY2030.
The May 8 annual stockholders meeting and Q1 2026 earnings, where North American category trends and Hill’s post-private-label volume growth will first show up in reported numbers, are the key datapoints confirming whether the TIKR model’s EPS ramp is on track.
Should You Invest in Colgate-Palmolive Company?
The only way to really know is to look at the numbers yourself. TIKR gives you free access to the same institutional-quality financial data that professional analysts use to answer exactly that question.
Pull up CL stock and you’ll see years of historical financials, what Wall Street analysts expect for revenue and earnings in the quarters ahead, how valuation multiples have moved over time, and whether price targets are trending up or down.
You can build a free watchlist to track Colgate-Palmolive Company alongside every other stock on your radar. No credit card required. Just the data you need to decide for yourself.
Access Professional Tools to Analyze CL stock on TIKR for Free →
